Seroatlas · Human Serome Atlas

ALAS2

5-aminolevulinate synthase, erythroid-specific, mitochondrial

Also known as: ALAS-E, ASB, HEM0_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P22557
Gene
ALAS2
Ensembl
ENSG00000158578
Chromosome
X
Canonical length
587 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
Quaternary structure
Homodimer

OverviewNCBI Gene

The product of this gene specifies an erythroid-specific mitochondrially located enzyme. The encoded protein catalyzes the first step in the heme biosynthetic pathway. Defects in this gene cause X-linked pyridoxine-responsive sideroblastic anemia. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

587 residues, UniProt reviewed canonical sequence.

>P22557|ALAS2
     1  MVTAAMLLQC CPVLARGPTS LLGKVVKTHQ FLFGIGRCPI LATQGPNCSQ IHLKATKAGG
    61  DSPSWAKGHC PFMLSELQDG KSKIVQKAAP EVQEDVKAFK TDLPSSLVSV SLRKPFSGPQ
   121  EQEQISGKVT HLIQNNMPGN YVFSYDQFFR DKIMEKKQDH TYRVFKTVNR WADAYPFAQH
   181  FSEASVASKD VSVWCSNDYL GMSRHPQVLQ ATQETLQRHG AGAGGTRNIS GTSKFHVELE
   241  QELAELHQKD SALLFSSCFV ANDSTLFTLA KILPGCEIYS DAGNHASMIQ GIRNSGAAKF
   301  VFRHNDPDHL KKLLEKSNPK IPKIVAFETV HSMDGAICPL EELCDVSHQY GALTFVDEVH
   361  AVGLYGSRGA GIGERDGIMH KIDIISGTLG KAFGCVGGYI ASTRDLVDMV RSYAAGFIFT
   421  TSLPPMVLSG ALESVRLLKG EEGQALRRAH QRNVKHMRQL LMDRGLPVIP CPSHIIPIRV
   481  GNAALNSKLC DLLLSKHGIY VQAINYPTVP RGEELLRLAP SPHHSPQMME DFVEKLLLAW
   541  TAVGLPLQDV SVAACNFCRR PVHFELMSEW ERSYFGNMGP QYVTTYA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ALAS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.34
Highest tissue expression
571 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 571 nTPM
  • placenta: 42 nTPM
  • spleen: 25 nTPM
  • tongue: 17 nTPM
  • lung: 5.4 nTPM
  • liver: 3.4 nTPM

Single-cell type

  • erythrocytes: 1,762 nCPM
  • erythrocyte progenitors: 375 nCPM
  • hematopoietic stem cells: 3.4 nCPM
  • cholangiocytes: 3.3 nCPM
  • megakaryocyte-erythroid progenitors: 1.9 nCPM
  • cdc: 1.3 nCPM

Immune cell

  • total PBMC: 5.9 nTPM
  • plasmacytoid DC: 1.6 nTPM
  • MAIT T-cell: 0.2 nTPM
  • memory B-cell: 0.2 nTPM
  • neutrophil: 0.2 nTPM
  • gdT-cell: 0.1 nTPM

Brain region

  • cerebral cortex: 3.9 nTPM
  • choroid plexus: 3.1 nTPM
  • medulla oblongata: 3.1 nTPM
  • spinal cord: 2.9 nTPM
  • pons: 2.8 nTPM
  • midbrain: 2.3 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ALAS2.

Disease | AllUniProt

Conditions ALAS2 is implicated in, by any mechanism.

Disease | GeneticClinVar

50 pathogenic / likely-pathogenic of 415 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.18
gnomAD pLI
1
gnomAD missense Z
2.37
DepMap mean gene effect
0.07
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ALAS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ALAS2 as an antibody target. Whether an autoantibody or antibody against ALAS2 could matter depends on whether native ALAS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ALAS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ALAS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/ALAS2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...